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Four signature groups of frequently occurred single-nucleotide variants (SNVs) were
identified in over twenty-eight thousand high-quality and high-coverage SARS-CoV-
2 complete genome sequences, representing different viral strains. Some SNVs
predominated but were mutually exclusively presented in patients from different
countries and areas. These major SNV signatures exhibited distinguishable evolution
patterns over time. A few hundred patients were detected with multiple viral strain-
representing mutations simultaneously, which may stand for possible co-infection
or potential homogenous recombination of SARS-CoV-2 in environment or within
the viral host. Interestingly nucleotide substitutions among SARS-CoV-2 genomes
tended to switch between bat RaTG13 coronavirus sequence and Wuhan-Hu-1
genome, indicating the higher genetic instability or tolerance of mutations on those
sites or suggesting that major viral strains might exist between Wuhan-Hu-1 and
RaTG13 coronavirus.
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INTRODUCTION
A novel betacoronavirus SARS-CoV-2 (Viruses CSGotICoTo, 2020) causing human coronavirus
disease 2019 (COVID-19) was first reported in Wuhan, Hubei China in December 2019 (Wu et al.,
2020a; Zhou et al., 2020; Zhu et al., 2020). The pandemic of SARS-CoV2 has infected more than
12 million people over 180 countries and areas around the world with a death over a half million as
of July 9, 2020 (Dong et al., 2020). The most vulnerable group in this COVID-19 pandemic is elderly
and those with different underlying medical conditions such as malnourish, hypertension, diabetes,
cancer and cardiovascular abnormality (Guzik et al., 2020). Much effort has been devoted by
scientists all over the world to understand the features of SARS-CoV2, particularly the viral genome
variations. In some cases, viral genomic mutations play a key role in propagation of SARS-COV-2.
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Viral mutation may alter the viral infectivity and pose an
additional challenge for detection by the host cell, and thus
it is critical to identify these mutations, especially in the
context of vaccine design and drug development. Similar to
other viruses, SARS-CoV-2 has been creating random mutations
on the genome over time. Only some of mutations were
caught and corrected by the virus’s error correction machinery
(Kupferschmidt and Cohen, 2020). Analysing these data can
potentially monitor the viral transmission routes and identify
novel mutations associated with the transmission (Zhang et al.,
2020a). For example, Given 103 earlier genome sequence data,
at least two clades of SARS-CoV-2 were found to be involved
in the global transmission based on T > C mutation on a
singleton site at 28144 of the complete genome, which was further
termed as S clade (C28144) and L clade (T28144) (Tang et al.,
2020). Evolutionary analyses suggested S clade appeared to be
more related to coronaviruses in animals. Most recently, three
major clusters of SNVs involved in the pandemic were found by
comparing 160 SARS-CoV-2 genomes (Sanchez-Pacheco et al.,
2020) with RaTG13 (Forster et al., 2020a). Researchers also
employed standard phylogenomic approaches and compared
consensus sequences representing the dominant virus lineage
within each infected host (Forster et al., 2020a; Lai et al., 2020).
Such information will be of important value for the development
of vaccine, transmission monitoring and ultimately the control
of the pandemic. However, most of these studies were based
on limited numbers of SARS-CoV-2 genomes collected during
early pandemic time, which might lead to debating conclusions
(Chookajorn, 2020; Forster et al., 2020b; Kupferschmidt, 2020;
Mavian et al., 2020; Rambaut et al., 2020; Sanchez-Pacheco et al.,
2020). To date, more than 40,000 SARS-CoV-2 whole genome
sequences have been uploaded to the online platform The Global
Initiative on Sharing Avian Influenza Data (GISAID) database1
(Elbe and Buckland-Merrett, 2017; Shu and McCauley, 2017).
With the availability of increased sample size following SARS-
CoV-2 spreading to almost all countries/areas in the world, it is
feasible to provide a comprehensive and updated analysis of the
viral genetic variations.
In this study, we took advantage of the mega-datasets
collected by GISAID which published almost thirty thousand
high-quality SARS-CoV-2 genomes with high coverage until
June 15, 2020. Our comprehensive analyses clearly revealed
distinct patterns of four major group mutations prominent in
different countries and areas, suggesting representative SARS-
CoV-2 strains correspondingly. We uncovered novel dynamic
transmission and evolution patterns for groups of SARS-CoV-
2 variants. A few hundred patients were found to have multiple
groups of mutations simultaneously. Comparing with four bat
coronavirus genomes, we found that alternations of nucleotides
on SARS-CoV-2 genome tend to occur at the same sites where
bat coronavirus sequences were different from Wuhan-Hu-1.
Strikingly, some nucleotide substitutions on SARS-CoV-2 were
apt to be the same as RaTG13 coronavirus sequences. We further
investigated protein structure alternations caused by the amino
acid (AA) changes due to high-frequent non-synonymous SNVs.
1https://www.gisaid.org/
Our novel genome-wide discoveries provided more detailed
information and shed the light of studying SARS-CoV-2 which
has been clouding over the world.
MATERIALS AND METHODS
Collection of Sequences
Complete high-coverage coronavirus sequences were
downloaded from GISAID database as of June 15, 2020.
28,212 coronavirus genomes isolated from humans and four bat
Rhinolophus affinis were analyzed, including Bat CoVRaTG13
and RmYN02 from Yunnan Province, China, SL-CoVZC45, SL-
CoVZXC21 from Zhejiang Province, China. White spaces within
the sequences were removed. We aligned these sequences using
minimap2 (Li, 2018) with the reference, the complete genome
of Wuhan-Hu-1 (GISAID ID EPI_ISL_402125) by Wu et al.
(2020a,b). The variants were annotated by ANNOVAR (Wang
et al., 2010) using NCBI Reference Sequence: NC_045512.2.
Mutation Rate
Mutation rate is an important factor to monitor virus
propagation and evolution (Zhao et al., 2004). In this study,
we compared all other SARS-CoV-2 genome sequences against
Wuhan-Hu-1 genome only. Hence we modified the formula






(N − 1) L
× 365
where µ is the mutation rate per site per year, N is the
total genomes collected after Wuhan-Hu-1 with detailed time
information, mi is number of mutations of ith genome compared
to Wuhan-Hu-1, ti is the time difference in days when ith genome
was collected after Wuhan-Hu-1, and L is the total length of
SARS-CoV-2 genome (L = 29903).
Circos Plot
Circos plot (Krzywinski et al., 2009; Gu et al., 2014) was made
given the ratios of genomes with SNV at each genome location of
SARS-CoV-2. The concurrence ratio between two SNVs, X and
Y, was defined as the ratio of the numbers of samples with both X
and Y to the minimal number of samples with either X or Y.
Concurrence ratio (X,Y) =
|X ∩ Y|
min (|X| , |Y|)
The connection lines in the Circos plot represent SNV pairs with
high concurrence ratios (larger than 0.9).
Clustering of SNVs
Two-way clustering was performed to categorize the SNVs and
samples with a distance function of one minus concurrence ratio
on 54 frequent SNVs and about twenty-eight thousand samples.
Enrichment Analysis
While comparing SARS-CoV-2 genomic mutation sites and sites
where Wuhan-Hu-1 varying from bats’ coronavirus, we used
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hypergeometric model to calculate the statistical significance
of the overlaps.
Protein Structure Analysis
We used PyMOL (Schrödinger, Inc.) to visualize and analyze
protein structure for WT (Wuhan-Hu-1) and mutations.
Mutagenesis tools in PyMOL was utilized to detect if a clash
was generated upon mutation. Properties of AAs were retrieved
from the “Table of standard amino acid abbreviations and
properties” on the Wikipedia2. The solved structures of Spike,
nsp3, nsp5, nsp7 and Pol were downloaded from Protein
Data Bank (PDB) (Berman et al., 2003): 6vyb for Spike using
electron microscopy (Walls et al., 2020), 6w6y for nsp3 using
X-ray diffraction method (Michalska et al., 2020), 6lu7 for
nsp5 using X-ray diffraction method (Jin et al., 2020), 6wqd
for nsp7 using X-ray diffraction method (Kim et al., 2020),
6m71 for Pol using electron microscopy (Gao et al., 2020).
Structures of other proteins, e.g., nsp2, nsp4, nsp6, Hel, ExoN,
ORF3a, M, ORF8, and N, were predicted by C-I-Tasser model3
(Yang et al., 2015; Huang et al., 2020; Zhang et al., 2020b):
QHD43415_2 for nsp2, QHD43415_4 for nsp4, QHD43415_6
for nsp6, QHD43415_12 for Hel, QHD43415_13 for ExoN,
QHD43417 for ORF3a, QHD43419 for M, QHD43422 for ORF8,
and QHD43423 for N.
RESULTS
Genetic Variants of SARS-CoV-2
We downloaded and analyzed 28,212 SARS-CoV-2 complete
genome sequences after excluding low-coverage ones from
the GISAID database. Using Wuhan-Hu-1 (NCBI Reference
Sequence: NC_045512.2, GISAID ID: EPI_ISL_402125) as
reference genome, we found that total 12,649 nucleotide sites had
single nucleotide variants (SNVs) when compared to reference
genome. The mutation rate was 1.1 × 10−3 per site per year for
all point mutations, while it became 1.0 × 10−3 if we removed
SNVs which appeared only once. Both sequence substitution
rates were in the same range as 0.80–2.38 × 10−3 for SARS-CoV
genome as reported (Zhao et al., 2004). Majority of SNVs had very
low occurrence frequency (Figure 1A), suggesting a high chance
of random or unstable mutations. Four nucleotide substitutions
were detected in over 70% of genome sequences: A23403G,
C3037T, C14408T, and C241T. They distributed at distinct
SARS-CoV-2 genome locations, on the gene body of Spike,
ORF1a, and ORF1ab, and upstream of ORF1ab, respectively.
Additionally, there were other 50 unique SNVs arose from larger
than 1% of populations (n > 282). It is interesting that some
of these frequent SNVs occurred almost simultaneously with
concurrent ratio larger than 0.9 (see methods) as shown by
blue-line connections in Figure 1A. They may appear across
different proteins. For example, A23403G changes an aspartate
to a glycine on Spike (D614G) while C14408T converts a proline
to a leucine on ORF1ab (P4715L). Over 99% of both SNVs were
2https://en.wikipedia.org/wiki/Amino_acid
3https://zhanglab.ccmb.med.umich.edu/COVID-19/
found simultaneously on more than 74% samples, suggesting a
biological connection between these concurrent variant sites.
Among total 54 frequent SNVs, 31 mutations are non-
synonymous variants or non-frameshift substitutions
(Figure 1B). Some of them have been discussed separately
by previous studies (Forster et al., 2020a; Guan et al., 2020; Tang
et al., 2020) or marked as elements in clades G, S, and V from
the GISAID report (Elbe and Buckland-Merrett, 2017; Shu and
McCauley, 2017). Here, two-way clustering was performed on 54
frequent SNVs and about 28,000 samples (Figure 1B). It is clear
to see four major groups of SNVs covering almost all samples,
including groups A (C14408T/A23403G, occurring on 21,116
samples), B (T28144C on 2,802 samples), C (G11083T/G26144T
on 3,173 samples), and D (G1440A/G2891A on 441 samples).
Most SNVs belonged to one unique cluster, while a few SNVs
crossed different groups. Taken as an example, a synonymous
mutation C14805T existed in both group B and C (Figure 1B),
covering over 8% of worldwide samples. Majority (79%) of
C14805T can be another signature mutation in group C
with SNVs G11083T and G26144T together. In general, the
geographical locations of infected patients bearing these special
groups of mutations were very different.
Forty countries and areas with numbers of viral genomes
larger than 50 were chosen to probe the geographical
distributions of these SNVs. Group A, represented by two
non-synonymous mutations, A23403G and/or C14408T, was
borne in totally 72% of samples in the study, including about 82%
from Europe and 67% from North America (Figure 1B). The top
three countries with the highest ratio in group A (Figure 2A)
were Russia (99%), Denmark (96%), and South Africa (96%).
Group B was distinguished by non-synonymous mutation
T28144C (Figure 1B) which results in substitution of a leucine
by a serine on ORF8. It was projected in Thailand (50%), Spain
(41%), China (31%), and some other Asian countries/areas
(Figure 2B). Group C was featured by two non-synonymous
SNVs, G11083T and G26144T (Figure 1B), which substituted
a leucine with a phenylalanine on ORF1ab and a glycine with a
valine on ORF3a, respectively. This group existed in many Asian
and European countries/areas, e.g., Hong Kong, Singapore,
Japan, Turkey etc. (Figure 2C), as reported previously (Elbe and
Buckland-Merrett, 2017; Shu and McCauley, 2017; Forster et al.,
2020a; Guan et al., 2020; Tang et al., 2020). Group D includes
two non-synonymous SNVs, G1440A and G2891A (Figure 1B),
both of which change the AA sequences on ORF1ab. It confirms
the clade D, previously defined by Guan et al. (2020) based on
smaller set of patients. G1440A led to the AA change, G212D on
non-structural protein 2 (nsp2), while G2891A caused A58T on
non-structural protein 3 (nsp3). D-group was mainly found in
several European countries/areas, e.g., Wales (17%), Germany
(10%), and Belgium (5%) (Figure 2D).
Besides signature variants in each major group discussed
above, some SNVs were found in relatively smaller populations
but concurred with the major signature SNVs. Importantly, many
non-major SNVs were mutually exclusively presented with each
other in different countries and areas (Figure 1B). For instance,
about 28 mutations coinciding with A23403G and C14408T in
the group A composed sub-types of A (Figure 1B), e.g., G25563T
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FIGURE 1 | SNVs on about thirty thousand SARS-CoV-2 complete genomes. (A) Circos plot shows distribution, frequency, and co-occurrences of SNV2. From
outer to inner circle: coronavirus genome location (nt), gene annotation, occurrence ratios of SNVs at the site (log10 scale, red bars), and connections with high
concurrence rates (>0.9) represented by blue lines. The darker the blue lines, the higher concurrence rates. (B) Fifty-four high frequent SNVs with annotated AA
changes were detected (in purple) in about twenty-eight thousand patients worldwide. Four major clusters of SNVs and consequent subgroups can be formed to
represent patients from different geographical locations.
and C1059T. However, two separable sets of samples were
associated with different combinations of G25563T and C1059T
(Figure 2A). Sub-cluster A1 included both G25563T and C1059T,
whereas sub-cluster A2 had G25563T but excluded C1059T. They
may represent divergent strains found in distinct populations
from varied countries/areas. Specifically, A1 occurred in 21%
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FIGURE 2 | Frequencies of signature SNVs in worldwide and top three countries/areas. (A–D) Four major groups and/or their sub-groups had distinct representing
countries/areas, indicating different transmission sources and evolution paths.
of all SAR-CoV-2 genomes collected world widely, particularly
in 71% of Denmark, 54% of Israel, and 52% of United States,
whereas A2 was found in only 6% population, which were mostly
discovered in Saudi Arabia (71%), Turkey (37%), and Columbia
(30%). Another sub-cluster, A3, had consecutive mutations
at positions 28881-28883 on SARS-CoV-2 complete genome,
leading non-frameshift substitutions on ORF9: R203K-G204R.
A3 occupied 25% of worldwide cases, represented by three
major countries, Brazil (81%), Bangladesh (78%), and Russia
(67%). Even though some sub-clusters of mutations were found
in smaller worldwide populations (around or lesser than 5%),
they were significantly over-represented in several countries and
areas. For instance, A4 with synonymous mutation C15324T
was detected in 61% samples of an African country, Democratic
Republic of the Congo (DRC), coming together with 36% of
Switzerland and 30% of France.
Patients from one country may have different main groups
or sub-types of mutations. A synonymous A20268G in cluster
A5 (Figure 2A) was sampled in Spain (39%), Iceland (20%),
and Scotland (20%). It is interesting that other 41% of Spain
samples had another distinguished non-synonymous mutation
T28144C in group B (Figure 2B), same as many samples
from Asian patients. It suggests the viral transmission path
on these patients. 31% of Spain samples also had another
unique mutation, C28863T, substituting a serine with a
leucine on ORF9, concurrent with T28144C. About 18% of
Australia samples were found in group B as well. But they
came with additional diverse mutually exclusive SNVs, e.g.,
either C18060T/A17858G/C17747T (7%), or C28863T (6%), or
G28077C (3%) as shown in Figure 2B. Similar scenarios were
observed in United States, where approximately 18% of samples
encompassed T28144C with C18060T/A17858G/C17747T, while
another 2% was recognized with a different non-synonymous
mutation G28077C in the same main group B (Figure 2B).
SNVs in group C including G11083T and G26144T existed in
many Asian countries and areas (Figure 2C), such as Hong Kong,
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Singapore, Japan, Indian, Taiwan, and Turkey, as reported
previously (Forster et al., 2020a). However, different countries
and areas were distinguished by extra variants in the same prime
group C. For example, 51% of Singapore was detected with non-
synonymous C28311T on ORF9, while Turkey had 32% samples
with non-synonymous G1397A on ORF1ab.
Currently, it lacks sufficient evidences to make a conclusive
statement about the origins of all SARS-CoV-2 mutations. But
time-annotated data collections can still explore geographical
evolution patterning of specific SNVs, albeit limited number
of high-quality and high-coverage sequenced viral genomes at
some time points. For example, only three cases with mutations
T28144C and C18060T (one sub-type in group B) reported in
Washington State of United States in January 2020, in addition
to eight cases in China and additional one in Singapore at almost
the same time (Figure 3A). It is notable that T28144C and
C18060T concurred with additional de novo non-synonymous
mutations C17747T/A17858G on ORF1ab in 51 cases from
United States and another one from the cruise of Grand
Princess in February 2020. No such case was detected in
other countries/areas. One month later, this group of signature
variants spread over many states of United States, particularly
west coast of United States, and other countries and areas
of different continents, including Canada, Australia, Iceland,
Mexico, New Zealand, and England etc.
Over half of American patients had been sampled with
mutations C14408T/A23403G and C1059T on SARS-CoV-2
genome (Figure 2A). Retrieving data in January 2020, we found
only one case with both C14408T and A23403G in China from
our dataset (Figure 3B). The first case in United States was
reported in New Hampshire at the east coast concurrently with
C1059T, in addition to five in France, one in Belgium and one in
Senegal. The numbers of such cases boosted up in United States
and other countries/areas in March 2020, including 354 in
Denmark, 164 in Australia, and 98 in France, 77 in England, etc.
In the United States, approximately 1,000 cases were found on the
east coast of United States, while over 400 cases were identified on
the west coast as well.
The variants of group A (C14408T/A23403G) indicated at
least two strains of SARS-CoV-2 distinguishable on the sites of
Spike and ORF1ab. One viral strain observed from Wuhan-Hu-
1 can be named as DP with an aspartate on 614 of Spike and a
proline on 4715 of ORF1ab, while another potential one, named
as GL, had a glycine on the site of 614 on Spike and a leucine on
the site of 4715 on ORF1ab instead. The ratio of GL strain in all
United States cases increased dramatically from 6% in February
to 87% in May and June 2020 (Figure 3C). The similar growing
trend was observed in most of other countries, regardless when
this group of mutations were first present (Figure 3C). In general,
91% of samples from all these countries had strain GL since May
2020 compared to only 3% in February (Figure 3D), suggesting
that the GL strain of SARS-CoV-2 might become much more
stable and prevailing than the other strain DP like Wuhan-Hu-1
after 6-month evolution and transmission.
Different groups of mutations also exhibited distinguished
evolution patterns (Figures 3C,D). Taking B-group SNVs for
example, we found that the ratio decreased over time from
35% in January 2020 to almost zero in June in these countries,
indicating that at least two strains existed at the early of COVID-
19 pandemic. However, strains including variant at 28,144
other than Wuhan-Hu-1 almost diminished after 7 months
of transmission. Only the strain that has the same nucleotide
T28144 as Wuhan-Hu-1 finally became the most stabilized strain
in the host. The similar patterns were observed for groups C and
D as well, even though a sudden increasing was found in February
and/or March 2020 due to unknown reasons. For instance, in
group C with SNVs G1440A and G2891A, Germany had a high
ratio, 47.8% (11 out of 23), in February, while 25% of (96 out of
384) Wales were sampled with the same variants in March 2020.
Four main groups of mutations showed mutually exclusive
in about twenty-eight thousand patients, indicating at least five
unique viral strains (including the one same as Wuhan-Hu-1)
potentially existed in the host. However, as reported in early
of March 2020, a patient hospitalized in Iceland infected by
two SARS-CoV-2 subtypes simultaneously4. One strain of the
SARS-CoV-2 coronavirus was more aggressive, according to
Reykjavik Grapevine newspaper citing CEO of CODE Genetics
biopharmaceutical company Kari Stefansson. The second strain
is a mutation from the original version of the coronavirus that
appeared in Wuhan, China. This was regarded as the first known
case of co-infection. Gudbjartsson et al. (2020) reported that
patient T25 carries both the A2a1a strain and the A2a1a+ 25958
strain. As shown in Figure 4, we found that 13 genomes bore both
A-group and B-group mutations, while 347 genomes had variant
groups of A and C, and both B and C groups were involved in
44 genomes. Strikingly, one patient from Spain was detected with
three groups of variants simultaneously, A–C. 17 and 4 out of 441
SARS-CoV-2 genomes with D-group SNVs were overlapped with
groups A and C, respectively.
Comparison of Variants Between
SARS-CoV-2 Genomes and Bat
Coronavirus Sequences
Bats were regarded as reservoir species for SARS-CoV-2. To
understand potential associations between SNVs among SARS-
CoV-2 genomes from patients and bat coronavirus sequences,
we also aligned four bat coronavirus sequences to Wuhan-Hu-
1 complete genome. The ratios of variants between Wuhan-
Hu-1 and bats were 3.8% (RaTG13), 11.1% (bat-SL-CoVZC45),
11.1% (bat-SL-CoVZXC21), and 4.8% (RmYN02). As described
above, 12,649 out of 29,903 nts (42.3%) on SARS-CoV-2 genome
underwent variation among about 28,000 samples. Interestingly,
the ratios of SARS-CoV-2 SNVs on the sites where bats’
sequences differed from Wuhan-Hu-1 were significantly elevated
(Figure 5A). Among them, RaTG13 reached the highest ratio
(61.5%) with p = 2.7e-40. The result suggests that the sites where
Wuhan-Hu-1 differed from bats might have higher tolerance for
sequence variations or higher genetic instability.
In theory, 12,649 identified SARS-CoV-2 SNVs can potentially
turn to be any one of three nucleotides other than the original
ones from Wuhan-Hu-1. When we focused on the sites where
4https://www.mbs.news/a/2020/03/icelandic-man-reportedly-caught-two-
coronavirus-subtypes-simultaneously.html
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FIGURE 3 | SNVs migration and evolution patterns over time. (A) SNV T28144C with C18060T and additional C17747T/A17858G spread in United States and
other countries/areas from January to March of 2020. (B) SNVs of C14408T and A23403G with C1059T spread in United States and other countries/areas from
January to March of 2020. (C) The ratios of four significant groups of SNVs, (A–D) in Figures 1 and 2, varied in different countries/areas with time development.
(D) Average temporal ratios of groups (A–D) SNVs show distinct patterns from January to June of 2020.
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FIGURE 4 | Number of patients carrying significant groups (A–D) of SNVs, indicating potential co-infection by different SARS-CoV-2 strains.
FIGURE 5 | Comparison between SARS-CoV-2 SNVs and nucleotides of bats (RaTG13, bat-SL-CoVZC45, bat-SL-CoVZXC21, and RmYN02) coronavirus varying
from Wuhan-Hu-1. (A) Percentage of SARS-CoV-2 SNVs on different regions, including SARS-CoV-2 complete genome, and sites where bats coronavirus differ
from Wuhan-Hu-1; (B) Percentage of SARS-CoV-2 SNVs which converted to bats nucleotides within the same regions as shown in (A).
bats coronavirus sequences differed from Wuhan-Hu-1, it turned
out that SARS-CoV-2 SNVs had the same mutated nucleotides
as RaTG13 coronavirus does on 503 out of 1,132 (44.4%) sites
where RaTG13 coronavirus sequence differed from Wuhan-Hu-
1 (Figure 5B), including C29095T (Forster et al., 2020a) and
seven high frequent SNVs identified from our major groups, e.g.,
C2416T and C3037T from group A, C8782T, C18060T, C24034T,
and T28144C from group B, and C23929T in group C. The
ratio for RaTG13 coronavirus was much higher than the ratios
observed in other three bat coronavirus sequences (32.0, 31.4, and
34.9%, respectively).
SARS-CoV-2 SNVs and Protein Functions
Viral sequence mutations will likely affect viral infection,
replication, and/or propagation, and thus alter SARS-CoV-2
transmission properties and COVID-19 severity. As previous
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reported, S68F and P71L non-synonymous mutation in E-protein
of SARS CoV-2 were the most common mutation in in
E-protein (Hassan et al., 2020); Q57H, G251V, and G196V
non-synonymous mutation in ORF3a of SARS-CoV-2 would
link to the virulence, infectivity, ion channel activity and viral
release (Issa et al., 2020); deletion of ORF8 leads to increased
production of the interferon and reduced level of inflammatory
cytokines (Chen et al., 2020; Gong et al., 2020; Li et al., 2020a).
Most recently, researchers found that D614G non-synonymous
mutation located in spike protein would increase infectivity
(Eaaswarkhanth et al., 2020; Li et al., 2020b; Yurkovetskiy et al.,
2020; Zhang et al., 2020c).
Here, we analyzed the structure changes of 31 high-frequent
non-synonymous SNVs and non-frameshift substitutions
(Figure 1B) using PyMOL (Schrödinger, Inc.). It was interesting
that all of them were on the surface area of corresponding
proteins (Table 1). Eight of them clashed with nearby AAs
on non-structural protein 2 (nsp2): G212D, nsp3: A58T, nsp4:
F308Y, nsp5: G15S, ORF3a: V13L and G251V, ORF9: G204R,
and Pol: A97V, which might be worthy of further analysis.
Six of SNVs on S: D614G, ORF3a: Q57H, ORF5: D3G, ORF9:
G204R, nsp2: G212D, nsp3: T1198K changed the charge upon
the mutations. These changes may contribute to transmission
and virulence of SARS-CoV-2. For example, a non-synonymous
SNV, G1440A in group D, discovered in over 400 samples from
several European countries, led to the AA change of G212D
on nsp2. Such a change of G212D may add clashes between
residues 212 and ASN183 (Figures 6A,B). It is interesting that
Nsp2 G212D falls on the region homologous to the endosome-
associated protein similar to the avian infectious bronchitis virus
(PDB 3ld1), which plays a key role in the viral pathogenicity
(Angeletti et al., 2020).
Similar to SARS coronavirus, SARS-CoV-2 enters into human
cells through the binding of its receptor-binding domain (RBD)
on Spike protein to human receptor ACE2 (Hoffmann et al.,
2020b). Furin is responsible for the proteolytic cleavage of
Spike protein to facilitate virus entry. In SARS-CoV-2, 15-nt
CCTCGGCGGGCACGT encodes five AAs: PRRAR (681-685),
locating at 23603–23617 of Wuhan-Hu-1 complete genome.
Furin cleavage site bears a RXXR pattern (Molloy et al., 1992;
Shiryaev et al., 2013). R685 makes an ideal furin proteolytic
cleavage site (Coutard et al., 2020). Out of almost thirty
thousand samples, 58 SARS-CoV-2 genomes were detected with
mutations in the region, including 13 from England and 23
from United States. Non-synonymous SNVs, C23604T, was most
frequent among others, causing the mutation of P681L. Other
AA mutations included P681H/L/S, R682Q/W, R683P/Q, and
A684E/T/S/V. As described previously, D614G on Spike caused
by the SNV A23403G in group A covered about three-quarter
of total sequenced genomes in our study. D614G on Spike
did not generate clashes from the protein structure predictions
(Figures 6C,D). However, the residue variations changed the
negative polar side chain to neutral non-polar side chain
(Figures 6C,D and Table 1). Since the site is close to the furin
region, such alternation might be able to affect the interactions
between furin and furin cleavage sites, then further influence
cell-cell fusion and ability to infection (Hoffmann et al., 2020a).
In addition, Cryo-EM-based structural analysis
(Wrapp et al., 2020) revealed that 5 key AAs within 434–
507 of Spike protein contributed most to the binding activity.
This was also confirmed by several recent cryo-EM structural
studies (Shang et al., 2020a,b; Wang et al., 2020a; Yuan et al.,
2020). The key AAs of SARS-CoV-2 RBD are: L455, G482,
V483, E484, G485, F486, Q493, S494, and N501. Interestingly,
we identified several non-synonymous SNVs of SARS-CoV-
2 on L455, V483, G485, and S494 from sequenced sample,
for instance, G22927T (L455F), G23009T (V483F), T23010C
(V483A), G23105A (G485S), and T23042C (S494P). Among
them, 28 viral genomes had mutation T23010C (V483A), all
of which were sampled in United States, including 26 from
Washington State. The RBD for SARS-CoV-2 has residues and
motifs found in all three clades in lineage B of betacoronavirus
(Letko et al., 2020), suggesting distinct cell entry pattern than that
of other clades. L455, G485, F486, and N501 are among contact
points of virus to human ACE2, changes in these positions may
affect the strength of transmission of the virus.
DISCUSSION
In this study, we comprehensively analyzed almost thirty
thousand high-quality and high-coverage SARS-CoV-2 complete
genome sequences as well as four bat genome sequences. Even
though some SNVs were reported previously and discussed
individually, we used bioinformatics approaches to systematically
identify four major mutually exclusive groups of SNVs among all
samples, suggesting at least five viral strains existing (including
one strain same as the reference). These mutations were detected
in populations from different geographical locations. The results
could provide some insights of possible new functions of SARS-
CoV-2 proteins and further bring therapeutic potentials.
Distinct time-course evolution patterns were observed for
four major groups of mutations. Some viral strains, e.g.,
GL with mutations C14408T and A23403G, may gradually
replace Wuhan-Hu-1, to become dominant after several month
evolutions. Or others may be eliminated naturally with time
development, e.g., strains associated with groups B–D mutations
(Figures 3C,D). It is hard to explain aberrant emergence of
some strains, e.g., the peak time of groups C and D in February
and March (Figures 3C,D), particularly due to the lack of
enough numbers of high-quality sequenced samples worldwide,
including China and other countries/areas, before February
2020. However, with more and more clinical data generated,
evolution patterning associated with specific biological functions
may be clearly uncovered. For example, several groups recently
reported that A23403G mutation in Spike protein might alter the
antigenic property and transmission ability due to the change
of Spike-ACE2 interaction (Becerra-Flores and Cardozo, 2020;
Korber et al., 2020a).
In general, four SNV clusters were mutually exclusively
presented. But we still noticed a few hundred patients who
were identified to carry multiple groups of SNVs simultaneously.
Without clear evidence that homologous recombination in
these regions in the intermediate or human host could occur
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117 Outer 42 No No
ORF3a Q57H Neutral Polar 146 Positive Polar 155 Outer 9 Yes No




131 Outer Val80 14 No No
ORF5/M D3G Negative Polar 133 Neutral Non-
polar
75 Outer −57 Yes Yes
ORF5/M T175M Neutral Polar 119 Neutral Non-
polar
149 Outer 30 No Yes
ORF8 S24L Neutral Polar 105 Neutral Non-
polar
131 Outer 26 No Yes
ORF8 L84S Neutral Non-
polar
131 Neutral polar 105 Outer −26 No Yes




131 Outer 16 No No
ORF9/N S194L Neutral Polar 105 Neutral Non-
polar
131 Outer 26 No Yes
ORF9/N S197L Neutral Polar 105 Neutral Non-
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ORF9/N R203K positive Polar 174 positive Polar 146 Outer −28 No No
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75 positive Polar 174 Inner Met411 100 Yes Yes
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131 Outer 12 No Yes Nsp2 T85I
ORF1ab G392D Neutral Non-
polar
75 Negative Polar 133 Outer Asn183 57 Yes Yes Nsp2 G212D
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polar
115 Neutral Polar 105 Outer −10 No Yes Nsp2 P585S
ORF1ab A876T Neutral Non-
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89 Neutral Polar 119 Outer Ile62 30 No Yes Nsp3 A58T
ORF1ab T1246I Neutral Polar 119 Neutral Non-
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131 Inner 12 No Yes Nsp3 T428I
ORF1ab T2016K Neutral Polar 119 positive Polar 146 Outer 28 Yes No Nsp3 T1198K
ORF1ab F3071Y Neutral Non-
polar
165 Neutral Polar 181 Outer Phe71 16 No Yes Nsp4 F308Y
ORF1ab G3278S Neutral Non-
polar
75 Neutral Polar 105 Outer Lys97 30 No Yes Nsp5 G15S
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ORF1ab Y5865C Neutral Polar 181 Neutral Polar 121 Outer −60 No No Hel/nsp13 Y541C




117 Outer 28 No No ExoN/nsp14 A320V
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FIGURE 6 | Structures of SARS-CoV-2 non-structural protein 2 (nsp2) and Spike near specific mutation sites. (A) No clash was predicted between nsp2 GLY212
and nsp2 ASN183 in Wuhan-Hu-1. (B) A clash was predicted between ASP212 and ASN183 after the mutation G212D. (C) There was interaction between T859
and D614. (D) No contact was precited between T859 and G614 after the mutation D614G.
in these viruses, we just defined such overlaps as potential
co-infections based on our observations and current knowledge.
One possibility is that two or three strains co-existed and
prevailed in the population of the same region during the
periods when the patients got infected from other people.
The patients could be first infected with one strain then
another one later, suggesting that primary infection did not
yield immunity in time against the subsequent infection
from a different strain. Another possibility is that the virus
underwent mutations during the transmission to another human
due to the special environment of the host, consequently
multiple representative mutations were present on the same
patient. There are several other scenarios in addition to co-
infections, including doubtful sequencing errors or cross sample
contaminations. Unfortunately, it lacks of enough information at
this moment about the potential post-infection immunity that
has important implications for the epidemiologic assessment
for the transmission (Kirkcaldy et al., 2020). Of course, the
percentage of co-infection cases was less than 1.5% in this
study. It might be the consequences of the quarantine and
lockdown policy enforced after the spread of COVID-19,
while social distancing and wearing face mask are considered
effective approaches in reducing the chance of co-infections
(Cheng et al., 2020; Eikenberry et al., 2020; Wang et al., 2020b;
West et al., 2020). These policies reduced the likelihood
that people met patients with different SARS-CoV-2 strains
at the same time.
We further compared SNVs among SARS-CoV-2 genomes
from human patients to bat coronavirus sequences. It is
interesting that SARS-CoV-2 SNVs, particularly those high-
frequent mutations, tend to occur at the same sites where bats
coronavirus sequences varied from Wuhan-Hu-1, suggesting
the high tolerance of these sites for genetic mutations, or
potentials of SARS-CoV-2 turning to a wild-type pathogenic
phenotype. RaTG13 coronavirus was most similar to SARS-
CoV-2 from perspective of sequences, but it held the highest
ratio of SARS-CoV-2 variants which converted to the bat’s
coronavirus sequences at the same sites. This suggests that
Frontiers in Microbiology | www.frontiersin.org 11 September 2020 | Volume 11 | Article 593548
fmicb-11-593548 September 23, 2020 Time: 16:41 # 12
Liu et al. SARS-CoV-2 Single Nucleotide Variants
some strains of SARS-CoV-2 deviated from Wuhan-Hu-1 might
be more similar to bat coronavirus RaTG13 than other bat
coronavirus strains presented in this paper. Of course, we don’t
have more evidence to show the exact connections between
them, but our results may shed the light to search intermediate
host and further understand the mechanisms of interspecies
transmission in future.
In addition to ORF proteins, four major structure proteins:
Spike (S), Envelope (E), Membrane (M), and Nucleocapsid (N),
help SARS-CoV2 in assembling and releasing new copies of
the virus within human cell. We found that all high-frequent
SARS-CoV2 SNVs occurred on the surface of proteins. One
of most frequent mutations, D614G, has been detected to be
dominant around the world now (Korber et al., 2020b). This
SNV caused more infections than other mutations (Li et al.,
2020b). Korber et al. (2020a,b) made suggestions from two
frameworks of the potential mechanism of being more infectious:
on the structure, D614G disconnects the connection between
614 in S1 and 859 in S2, which in turn facilitates the shedding
of S1 from viral-membrane-bound S2 or impacts RBD-ACE2
binding by influencing RBD positioning. On the immunological
aspect, D614 is within immunodominant linear epitope. Binding
of antibody to the epitope may incur conformational change
in Spike resulting in nearby enhanced RBD interaction with
ACE2. Since furin cleavage sites are essential for SARS-CoV-
2 infection of human, in addition to D614G, variants on or
nearby the furin cleavage sites may affect virus entry and spread
(Hoffmann et al., 2020a).
In summary, we attempted to uncover fundamental
genetic patterns of SARS-CoV-2 which may help us
understand functional consequences due to the viral genetic
instability. Our efforts in exploring the views of SARS-
CoV-2 migration and evolution in different geographical
locations can be helpful to fight against the pandemic.
Our findings may provide useful insights on SARS-CoV-2
replication, pathogenicity, and implications. We look forward
to incorporating our results with other studies, e.g., interaction
maps between SARS-CoV-2 proteins and human proteins
(Gordon et al., 2020), for drug discovery, antibody design or
vaccine development in near future.
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